Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 12, 2024, discloses the grant of conditional share awards to Persons Discharging Managerial Responsibilities (PDMRs) and their Persons Closely Associated (PCAs) under the GlaxoSmithKline 2017 Performance Share Plan. The awards were granted on February 8, 2024, covering a performance period of three financial years from January 1, 2024, to December 31, 2026.
Key Financial Metrics and Award Details
The filing does not report consolidated revenue, profit, cash flow, or debt metrics for the company. Instead, it details the valuation and volume of equity awards granted to senior executives.
- Instrument Type: Conditional awards of Ordinary Shares (GBP) and American Depositary Shares (USD).
- Valuation Date: February 8, 2024.
- Share Price: Ordinary Shares at £16.726; ADS at $42.02.
- Total Volume Granted: Approximately 2,182,891 Ordinary Shares and 57,636 ADS across 13 executives.
- Key Recipients: Includes CEO Emma Walmsley (468,449 shares), CFO Julie Brown (236,763 shares), and Chief Scientific Officer Anthony Wood (221,977 shares).
Material Changes and Performance Measures
The filing outlines the specific performance metrics determining the vesting of these awards, which align with the company's growth agenda. The vesting schedule is contingent on achieving targets over the 2024-2026 period.
Performance Measure Weightings
- Relative Total Shareholder Return (TSR): 30% (Ranked against 9 global pharmaceutical peers).
- Total Sales Growth: 20%.
- Adjusted Operating Profit Growth: 20%.
- Pipeline Progress: 20% (Split between pivotal trial starts and regulatory approvals).
- ESG: Environment: 10% (Climate and Nature Net Positive targets).
Vesting Thresholds: For Sales and Profit measures, the threshold for any vesting is 99% of the target. Maximum vesting (100%) requires achieving 105% of the target. Specific targets for Sales, Profit, and Pipeline Progress are deemed commercially sensitive and are not disclosed in this filing.
Guidance, Outlook, and Risks
Management commentary indicates a focus on innovation and commercial ambitions as outlined in the Investor Update. The filing notes that specific targets for Sales, Profit, and Pipeline Progress will be disclosed only at the end of the performance period. A key risk to investors is that if performance targets are not met, the conditional awards will lapse entirely. Additionally, Executive Directors are subject to a two-year holding period post-vesting, during which shares may be forfeited if terminated for cause.
Investor Verification Checklist
- Verify the specific TSR comparator group performance relative to GSK over the 2024-2026 period.
- Monitor future disclosures for the specific numerical targets for Total Sales and Adjusted Operating Profit Growth once the performance period concludes.
- Track progress on the six ESG KPIs (three Climate, three Nature) required for the 10% vesting component.
- Review the 2023 Annual Report for the detailed points vesting scales regarding the Pipeline Progress measure.
- Confirm the final vesting percentages for the 2024 awards in the 2027 Annual Report.